Table 1.
Patients characteristics.
| Characteristics | N (%) |
|---|---|
| All patients | 59 (100) |
| Age (median 50 years) | |
| ≤40 | 11 (19) |
| 41–50 | 19 (32) |
| 51–69 | 29 (49) |
| ≥70 | 0 (0) |
| Race/ethnicity | |
| White (non-Hispanic) | 35 (59) |
| Hispanic/Latino | 5 (8) |
| Black | 11 (19) |
| Asian/American Indian | 4 (6) |
| Unknown | 4 (6) |
| Clinical tumor size | |
| T1 | 21 (35) |
| T2 | 30 (51) |
| T3 | 8 (14) |
| Clinical nodal status | |
| cN0 | 31 (52) |
| cN1 | 25 (42) |
| cN2 | 1 (2) |
| cN3 | 3 (4) |
| Clinical stage at diagnosis | |
| I | 12 (20) |
| II | 33 (56) |
| III | 14 (24) |
| Histologic tumor grade | |
| G1 | 1 (2) |
| G2 | 12 (20) |
| G3 | 45 (76) |
| Unknown | 1 (2) |
| Durvalumab dose level | |
| 3 mg/kg | 4 (7) |
| 10 mg/kg | 55 (93) |
| Pathologic response | |
| pCR | 26 (44) |
| RD | 31 (53) |
| No surgery | 2 (3) |
| Residual cancer burden (RCB) | |
| RCB-I | 7 (12) |
| RCB-II | 18 (31) |
| RCB-III | 6 (10) |
| No surgery | 2 (3) |
| PD-L1 IHC | |
| Negative | 19 (32) |
| Positive (≥1%) | 33 (56) |
| Not available | 7 (12) |
| Stromal TIL count | |
| 0–10% | 28 (48) |
| 11–29% | 10 (17) |
| ≥30% | 16 (27) |
| Not available | 5 (8) |
TIL tumor-infiltrating lymphocytes, IHC immunohistochemistry.